Allergan's Restasis Defense Falters As PTAB Dismisses Tribal Immunity Ploy
The damage inflicted by Mylan and other manufacturers looking to sell Restasis generics already has been felt by Allergan, but the PTAB dealt the dry eye drug's patent defense another blow by rejecting the Mohawk Tribe's plea to have an inter partes review thrown out.
You may also be interested in...
Questions loom as to whether Allergan's pair of CGRP antagonists will face the liver toxicity issues that previously plagued oral CGRP drugs. The firm is counting on the migraine therapies to help offset revenues lost to generics.
US FDA rejects Allergan's third citizen petition seeking to require comparative clinical trials of generic versions of its dry eye medicine; company appeals patent invalidity ruling and PTAB admonishes Mohawk Tribe for its actions in IPR proceeding.
J.P. Morgan Notebook Day 1: Tax Reform At Last, Allergan's Job Cuts, Teva Turnaround, Biogen's Cash, And Getting FDA-Friendly
Daily round-up of news and notes from the 2018 J.P. Morgan Healthcare Conference in San Francisco: US corporate tax reform becomes a reality, Allergan's Saunders defends patent moves as a means of protecting jobs, clarity on generic prices from Teva, Biogen's money to burn, and making the most of FDA flexibility.